- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03147196
Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Neoadjuvant Treatment of Prostate Cancer With Bicalutamide and Raloxifene Prior to Radical Prostatectomy
Study Overview
Status
Detailed Description
PRIMARY OBJECTIVES:
I. To collect and interrogate samples in patients with prostate cancer that were diagnosed with prostate cancer and are planned for radical prostatectomy at Mayo Clinic Arizona.
SECONDARY OBJECTIVES:
I. To describe the adverse event profile and tolerance of therapy for 60 days of treatment prior to surgery.
II. To assess change in stage and/or grade of cancer and prostate specific antigen (PSA) response to neoadjuvant treatment in patients with hormone sensitive prostate cancer.
TERTIARY OBJECTIVES:
I. To evaluate specific pathways and changes when comparing biopsy specimens to prostatectomy.
II. To describe the quality of life of patients receiving hormonal therapy prior to radical prostatectomy.
OUTLINE: This is a dose-escalation study. Patients are randomized to 1 of 4 arms.
ARM A: Patients receive low dose raloxifene hydrochloride orally (PO) daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive low dose bicalutamide PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
ARM C: Patients receive low dose raloxifene hydrochloride PO daily and low dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
ARM D: Patients receive high dose raloxifene hydrochloride PO daily and high dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological confirmation of adenocarcinoma of the prostate, >= Gleason 6, clinical stage T1a-T2c and planned for radical prostatectomy
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
- Platelet count >= 50,000/mm^3
- Hemoglobin > 9.0 g/dL
- Creatinine =< 2.0 mg/dL
- Provide informed written consent
- Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
- Patients must also provide written consent for biospecimens collection on Institutional Review Board (IRB) 08-000980
Exclusion Criteria:
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
- History of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
- History of a venous thromboembolic event, cerebrovascular accident (CVA), hepatic impairment, or heart failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (raloxifene hydrochloride)
Patients receive low dose raloxifene hydrochloride PO daily on days 1-30.
Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Ancillary studies
Given PO
Other Names:
|
Experimental: Arm B (bicalutamide)
Patients receive low dose bicalutamide PO daily on days 1-30.
Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Ancillary studies
Given PO
Other Names:
|
Experimental: Arm C (raloxifene hydrochloride, bicalutamide)
Patients receive low dose raloxifene hydrochloride PO daily and low dose bicalutamide PO on days 1-30.
Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Ancillary studies
Given PO
Other Names:
Given PO
Other Names:
|
Experimental: Arm D (raloxifene hydrochloride, bicalutamide)
Patients receive high dose raloxifene hydrochloride PO daily and high dose bicalutamide PO on days 1-30.
Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Ancillary studies
Given PO
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Collection and interrogation of prostate cancer samples
Time Frame: Up to 5 years
|
Pathways and biomarkers will be compared to similar analyses that have been and will be performed on in vitro and in vivo experiments.
Point estimates and two-sided 95% confidence intervals will be computed.
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cancer stage/grade via surgical pathology
Time Frame: Baseline up to the time of prostatectomy
|
Will be calculated as the total number who were down staged divided by the number of total evaluable patients.
A confidence interval for this rate will be calculated based on properties of the binomial distribution.
Point estimates and two-sided 95% confidence intervals will be computed.
|
Baseline up to the time of prostatectomy
|
Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
Time Frame: Up to 30 days
|
The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns.
|
Up to 30 days
|
Percent change in PSA assessed by Prostate Cancer Clinical Trials Working Group
Time Frame: Baseline up to 12 weeks
|
Will be calculated and displayed using waterfall plots.
|
Baseline up to 12 weeks
|
Tolerance of therapy
Time Frame: Up to 60 days
|
Proportion of patients who complete 60 days of treatment will be calculated as the number of who completed 60 days of treatment divided by the total number of evaluable patients.
A confidence interval for this rate will be calculated based on properties of the binomial distribution.
The proportion of patients who experience a particular event will be calculated as the total number who experienced the event of interest divided by the number of total evaluable patients, with appropriate confidence interval.
|
Up to 60 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in quality of life assessed using the 6-item Linear Analogue Self-Assessment and the Hormonal Domain scale of the Expanded Prostate Cancer Index Composite survey
Time Frame: Baseline up to 5 years
|
Will be examined using stream plots and mean plots with associated two-sided 95% confidence intervals.
|
Baseline up to 5 years
|
Change in specific pathways and biomarkers
Time Frame: Baseline up to 5 years
|
Continuous biomarker levels will be explored in a graphical manner including mean plots and plots of change and percent change from baseline and other summary measures.
Any potential relationships between the baseline level or change in the level of each biomarker and clinical outcome will be further analyzed using Wilcoxon rank sum tests or logistic regression methods, as appropriate.
Association between a dichotomized biomarker and overall response will be assessed using a chi-squared test.
|
Baseline up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Erik Castle, Mayo Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Adenocarcinoma
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Bone Density Conservation Agents
- Estrogen Antagonists
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Androgen Antagonists
- Raloxifene Hydrochloride
- Bicalutamide
Other Study ID Numbers
- MC1552 (Other Identifier: Mayo Clinic in Arizona)
- P30CA015083 (U.S. NIH Grant/Contract)
- NCI-2017-00773 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage II Prostate Adenocarcinoma
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate AdenocarcinomaUnited States, Canada, Puerto Rico
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedStage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate AdenocarcinomaUnited States
-
Case Comprehensive Cancer CenterTerminatedAdenocarcinoma of Prostate | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingStage IIB Prostate Cancer | Stage II Prostate Adenocarcinoma | Stage III Prostate AdenocarcinomaUnited States
-
Dana-Farber Cancer InstituteCompletedProstate Cancer | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
University of California, San FranciscoCompletedProstate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7United States
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingProstate Adenocarcinoma | Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate AdenocarcinomaUnited States, Canada, Switzerland
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage III Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7United States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedProstate Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the ProstateUnited States
-
Andrei IagaruNational Cancer Institute (NCI)CompletedStage II Prostate Adenocarcinoma | Stage III Prostate AdenocarcinomaUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
National Cancer Institute (NCI)Recruiting
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingRecurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized OsteosarcomaUnited States